Comparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials

By afschroeder • June 25, 2026

Møller Jensen C, Zargari Marandi R, Moestrup KS, Mourad A, Mena Lora AJ, Sherman BT, Vock DM, Nordwall JA, Carson JM, Peiffer-Smadja N, Aggarwal NR, Naiman NE, Brown SM, Barrett TW, Hatlen T, Kjærgaard VS, Chang W, Sydes MR, Lundgren J, Jensen TO; STRIVE Network and ITAC and TICO Study Groups. Comparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials. JAMIA Open. 2026 Jun 23;9(3):ooag079. doi: 10.1093/jamiaopen/ooag079. PMID: 42344108; PMCID: PMC13289610.

Tags: biostatistics, Harbor UCLA, Infectious Diseases, machine learning, Medical Informatics, Publications, Randomized Controlled Trial, SARS-CoV-2

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review

Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United[...]

Response to the Letter to the Editor Entitled “Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy”

Giri K, Glassock RJ, Fervenza FC. Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy". Kidney Int[...]